NCT04705818View on ClinicalTrials.gov

Combining Epigenetic And Immune Therapy to Beat Cancer.

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

July 23, 2021

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions
Advanced Solid TumorAdvanced Colorectal CarcinomaAdvanced Soft-tissue SarcomaAdvanced Pancreatic AdenocarcinomaAdult Solid Tumor
Interventions
DRUG

Durvalumab

Durvalumab will be administered by intraveinous infusion (1120 mg) on day 1, every 3 weeks. Treatment by durvalumab will start on Day 22 (i.e., day 1 of cycle 2)

DRUG

Tazemetostat

Tazemetostat will be administered per-os, twice daily (800 mg x 2), continuously. Treatment by tazemetostat will start on day 1 (of cycle1).

Trial Locations (3)

29200

CHRU Brest, Brest

33076

Institut Bergonie, Bordeaux

86000

CHU Poitiers, Poitiers

Sponsors

Lead Sponsor

Institut Bergonié

Collaborators (2)

AstraZeneca
Epizyme, Inc.
All Listed Sponsors
collaborator

AstraZeneca

INDUSTRY

collaborator

Epizyme, Inc.

INDUSTRY

lead

Institut Bergonié

OTHER